[1]
|
Vannucchi, A.M. (2014) How I Treat Polycythemia Vera. Blood, 124, 3212-3220.
https://doi.org/10.1182/blood-2014-07-551929
|
[2]
|
中华医学会血液学分会白血病淋巴瘤学组. 真性红细胞增多症诊断与治疗中国专家共识(2016版) [J]. 中华血液学杂志, 2016, 37(4): 265-268.
|
[3]
|
Baxter, E.J., Scott, L.M., Campbell, P.J., et al. (2005) Acquired Mutation of the Tyrosine Kinase JAK2 in Human Myeloproliferative Disorders. Lancet, 365, 1054-1061. https://doi.org/10.1016/S0140-6736(05)74230-6
|
[4]
|
Kiladjian, J.J., Cassinat, B., Chevret, S., et al. (2008) Pegylated Interferon-Alfa-2a Induces Complete Hematologic and Molecular Responses with Low Toxicity in Polythemia Vera. Blood, 112, 3065-3072.
https://doi.org/10.1182/blood-2008-03-143537
|
[5]
|
Quintas-Cardama, A., Kantarjian, H., Manshouri, T., et al. (2009) Pegylated Interferon-Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients with Advanced Essential Thrombocythemia and Polycythemia Vera. Journal of Clinical Oncology, 27, 5418-5424. https://doi.org/10.1200/JCO.2009.23.6075
|
[6]
|
Mullally, A., Bruedigam, C., Poveromo, L., et al. (2013) Depletion of Jak2V617F Myeloproliferative Neoplasm- Propagating Stem Cells by Interferon-α in a Murine Model of Polycythemia Vera. Blood, 121, 3692-3702.
https://doi.org/10.1182/blood-2012-05-432989
|
[7]
|
Tomer, Y. and Menconi, F. (2009) Interferon Induced Thyroiditis. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 703-712. https://doi.org/10.1016/j.beem.2009.07.004
|
[8]
|
Fentiman, I.S., Thomas, B.S., Balkwill, F.R., et al. (1985) Primary Hypothyroidism Associated with Interferon Therapy of Breast Cancer. Lancet, 1, 1166. https://doi.org/10.1016/S0140-6736(85)92475-4
|
[9]
|
Mandac, J.C., Chaudhry, S., Sherman, K.E., et al. (2006) The Clinical an Physiological Spectrum of Interferon-Alpha Induced Thyroiditis: Toward a New Classification. Hepatology, 43, 661-672. https://doi.org/10.1002/hep.21146
|
[10]
|
Dalgard, O., Bjoro, K., Hellum, K., et al. (2002) Thyroid Dysfunction during Treatment of Chronic Hepatitis C with Interferon Alpha: No Association with Either Interferon Dosage or Efficacy of Therapy. Journal of Internal Medicine, 251, 400-406. https://doi.org/10.1046/j.1365-2796.2002.00974.x
|
[11]
|
Prummel, M.F. and Laurberg, P. (2003) Interferon-Alpha and Autoimmune Thyroid Disease. Thyroid, 13, 547-551.
https://doi.org/10.1089/105072503322238809
|
[12]
|
Koh, L.K., Greenspan, F.S. and Yeo, P.P. (1997) Interferon-Alpha Induced Thyroid Dysfunction: Three Clinical Presentations and a Review of the Literature. Thyroid, 7, 891-896. https://doi.org/10.1089/thy.1997.7.891
|
[13]
|
Koziclcwicz, D., Zalesna, A. and Dybowska, D. (2014) Can Pegylated Interferon α-2a Cause Development of Thyroid Disorders in Patients with Chronic Hepatitis B? Expert Opinion on Drug Safety, 13, 1009-1014.
https://doi.org/10.1517/14740338.2014.921156
|
[14]
|
Costelloe, S.J., Wassef, N., Schulz, J., et al. (2010) Thyroid Dysfunction in a UK Hepatitis C Population Treated with Interferon-Alpha and Ribavirin Combination Therapy. Clinical Endocrinology, 73, 249-256.
|
[15]
|
Fernandez-Soto, L., Gonzalez, A., Escobar-Jimenez, F., et al. (1998) Increased Risk of Autoimmune Thyroid Disease in Hepatitis C vs Hepatitis B before, during and after Discontinuing Interferon Therapy. Archives of Internal Medicine, 158, 1445-1448. https://doi.org/10.1001/archinte.158.13.1445
|
[16]
|
Parana, R., Cruz, M., Lyra, L., et al. (2000) Subacute Thyroiditis during Treatment with Combination Therapy (Interferon plus Ribavirin) for Hepatitis C Virus. Journal of Viral Hepatitis, 7, 393-395.
https://doi.org/10.1046/j.1365-2893.2000.00247.x
|